BioTE
Biote Corp., hormone-pellet franchise and provider network
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Compounded hormone pellets are not FDA-approved; no pellet has FDA approval
Reference only. Not medical advice.
What can go wrong
Non-FDA-approved delivery with non-titratable dosing; documented risks include supraphysiological hormone peaks, erythrocytosis, pellet extrusion, and infection at the implant site. The 2018 FDA inspection findings on unreported adverse events (potential associations with strokes, heart attacks, DVT, and cancers per the FDA statement) are a serious mark on the model's safety-surveillance history. Care quality varies across the certified provider network.
This is something to take to a clinician. The Atlas can tell you what is known about biote in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Biote is a hormone-optimization company built on a franchise-like model: it certifies and trains a large network of independent clinicians who then implant subcutaneous compounded hormone pellets (testosterone and estradiol) in their own practices, sourced through partner compounding facilities. No hormone pellet is FDA-approved, because pellets deliver variable, non-titratable hormone levels. A 2018 FDA inspection of BioTE Medical reportedly surfaced roughly 4,200 adverse events that had not been reported to the agency, associated with outcomes including cardiovascular events, thrombosis, and cancers, an adverse-event-reporting failure the FDA publicly highlighted.
A franchise model: certify thousands of clinicians, sell the pellets they implant.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Commercially, Biote sells to clinicians as much as to patients: it monetizes certification, training, and pellet supply across a broad provider network, so revenue scales with the number of certified practices and pellets implanted. Clinically, pellets are implanted subcutaneously and release hormone over months, which is the convenience pitch and also the core safety problem: once implanted, the dose cannot be adjusted or removed easily if levels run too high.
Non-titratable by design
The marketed convenience, one procedure every few months, is also the central risk. A pellet cannot be dose-adjusted after implantation; supraphysiological peaks early in the cycle followed by troughs are common, and there is no easy off-switch if hematocrit or estradiol climbs. Franchise-network variability means dosing and follow-up quality differ widely from clinic to clinic.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
Replacement is not the same as a cycle
Pellet dosing frequently produces supraphysiological testosterone peaks in the weeks after implantation, then declines. Because the dose cannot be withdrawn, supraphysiological exposure and its erythrocytosis/cardiovascular risks cannot be quickly corrected.
What it does to fertility
Testosterone pellets deliver exogenous testosterone and suppress spermatogenesis, impairing fertility like other forms of TRT; the non-titratable, months-long delivery makes rapid reversal impractical.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total and free testosterone
- Hematocrit / hemoglobin
- Estradiol
- PSA (age-appropriate)
- Implant-site assessment
What people get wrong
Often saidPellets are 'bioidentical' so they're safer and more natural
Actually'Bioidentical' describes molecular structure, not safety or approval. No hormone pellet is FDA-approved; pellets deliver inconsistent, non-titratable levels, and the model's adverse-event reporting has been criticized by the FDA.
Who profits, and who pushes back
U.S. FDA
Publicly highlighted that ~4,202 adverse events tied to compounded pellets marketed by BioTE were not reported to the agency, in a statement on improving adverse-event reporting for compounded drugs.
Biote Corp. (publicly traded) and its certified clinician franchisees; revenue from certification, training, and pellet supply across the network.
At a glance
- Model
- Certify/train clinician network; sell pellets they implant
- Product
- Subcutaneous compounded testosterone/estradiol pellets
- FDA approval
- None; no hormone pellet is FDA-approved
- 2018 FDA finding
- ~4,202 adverse events reportedly not reported to FDA
- Delivery
- Non-titratable; levels can run high then decline
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about BioTE. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.